StockDrifts LogoStockDrifts

Vistos 419540

Company
비스토스Vistos
Insiders
4
Buys
2
Total Value
₩631M ($438K)
Avg Return
+18.82%
Last Filing
2026-06-18

Vistos (419540) has 2 disclosed insider purchases and 44 disclosed disposals on record, filed by 4 distinct insiders. Together those filings cover ₩631M ($438K) in reported transaction value. The earliest filing StockDrifts holds for Vistos is dated 2023-03-29; the most recent is 2026-06-18. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +18.82%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-06-18BUY제3자배정유상증자
씨유메디칼
CU Medical
-1.4M₩3,170-5.5%₩4.3B ($3.0M)
2026-06-05BUYMarket Buy
씨유메디칼
CU Medical
-9.9K₩2,800+14.3%₩28M ($19K)
2026-05-20SELL주식병합
씨유메디칼
CU Medical
--6.2M₩4,385+27.0%₩27.3B ($19.0M)
2026-01-21SELLMarket Sell
박승기
Seunggi Park
moving-85₩1,300+20.1%₩111K ($77)
2026-01-21SELLMarket Sell
박승기
Seunggi Park
moving-40.0K₩1,300+20.1%₩52M ($36K)
2026-01-21SELLMarket Sell
박승기
Seunggi Park
moving-34.0K₩1,300+20.1%₩44M ($31K)
2026-01-21SELLMarket Sell
박승기
Seunggi Park
moving-240₩1,300+20.1%₩312K ($217)
2026-01-21SELLMarket Sell
박승기
Seunggi Park
moving-40.7K₩1,300+20.1%₩53M ($37K)
2026-01-21SELLMarket Sell
이한나
Hanna Lee
moving-10.0K₩1,300+20.1%₩13M ($9K)
2026-01-21SELLMarket Sell
박승기
Seunggi Park
moving-20.0K₩1,300+20.1%₩26M ($18K)
2026-01-21SELLMarket Sell
박승기
Seunggi Park
moving-10.3K₩1,300+20.1%₩13M ($9K)
2026-01-21SELLMarket Sell
박승기
Seunggi Park
moving-10.0K₩1,300+20.1%₩13M ($9K)
2026-01-21SELLMarket Sell
박승기
Seunggi Park
moving-9.8K₩1,300+20.1%₩13M ($9K)
2026-01-21SELLMarket Sell
박승기
Seunggi Park
moving-7.9K₩1,300+20.1%₩10M ($7K)
2026-01-21SELLMarket Sell
박승기
Seunggi Park
moving-1.5K₩1,300+20.1%₩2M ($1K)
2026-01-21SELLMarket Sell
박승기
Seunggi Park
moving-339₩1,300+20.1%₩441K ($306)
2026-01-21SELLMarket Sell
박승기
Seunggi Park
moving-293₩1,300+20.1%₩381K ($265)
2026-01-20SELL장외매도
이후정
Lee Hu-jeong
CEO-4.5M₩1,070+3.0%₩4.8B ($3.4M)
2026-01-20BUY장외매수
씨유메디칼
CU Medical
-7.8M₩1,070-3.0%₩8.3B ($5.8M)
2025-12-15SELLMarket Sell
박승기
Seunggi Park
moving-1.0K₩1,156+10.2%₩1M ($803)
2025-12-15SELLMarket Sell
박승기
Seunggi Park
moving-1.0K₩1,156+10.2%₩1M ($803)
2025-12-15SELLMarket Sell
박승기
Seunggi Park
moving-1.0K₩1,156+10.2%₩1M ($803)
2025-12-15SELLMarket Sell
박승기
Seunggi Park
moving-1.0K₩1,156+10.2%₩1M ($803)
2025-12-15SELLMarket Sell
박승기
Seunggi Park
moving-1.0K₩1,156+10.2%₩1M ($803)
2025-12-15SELLMarket Sell
박승기
Seunggi Park
moving-1.0K₩1,156+10.2%₩1M ($803)
2025-12-15SELLMarket Sell
박승기
Seunggi Park
moving-1.0K₩1,156+10.2%₩1M ($803)
2025-12-15SELLMarket Sell
박승기
Seunggi Park
moving-2.0K₩1,156+10.2%₩2M ($2K)
2025-12-15SELLMarket Sell
박승기
Seunggi Park
moving-2.0K₩1,156+10.2%₩2M ($2K)
2025-12-15SELLMarket Sell
박승기
Seunggi Park
moving-4.0K₩1,156+10.2%₩5M ($3K)
2025-12-15SELLMarket Sell
박승기
Seunggi Park
moving-5.0K₩1,156+10.2%₩6M ($4K)
2025-12-12SELLMarket Sell
박승기
Seunggi Park
moving-291₩1,145+9.3%₩333K ($231)
2025-12-12SELLMarket Sell
박승기
Seunggi Park
moving-5.3K₩1,145+9.3%₩6M ($4K)
2025-12-12SELLMarket Sell
박승기
Seunggi Park
moving-3.1K₩1,145+9.3%₩4M ($2K)
2025-12-12SELLMarket Sell
박승기
Seunggi Park
moving-2.7K₩1,145+9.3%₩3M ($2K)
2025-12-12SELLMarket Sell
박승기
Seunggi Park
moving-1.5K₩1,145+9.3%₩2M ($1K)
2025-12-12SELLMarket Sell
박승기
Seunggi Park
moving-1.3K₩1,145+9.3%₩2M ($1K)
2025-12-12SELLMarket Sell
박승기
Seunggi Park
moving-726₩1,145+9.3%₩831K ($577)
2025-12-10SELLMarket Sell
박승기
Seunggi Park
moving-588₩1,122+7.5%₩660K ($458)
2025-12-10SELLMarket Sell
박승기
Seunggi Park
moving-10.0K₩1,122+7.5%₩11M ($8K)
2025-12-10SELLMarket Sell
박승기
Seunggi Park
moving-3.1K₩1,122+7.5%₩4M ($2K)
2025-12-10SELLMarket Sell
박승기
Seunggi Park
moving-1.3K₩1,122+7.5%₩1M ($990)
2024-09-26SELLMarket Sell
강명진
Kang Myeong-jin
Managing Director-6.5K₩2,180+52.4%₩14M ($10K)
2024-09-25SELLMarket Sell
강명진
Kang Myeong-jin
Managing Director-11.0K₩2,165+52.1%₩24M ($17K)
2024-09-24SELLMarket Sell
강명진
Kang Myeong-jin
Managing Director-28.0K₩2,205+52.9%₩62M ($43K)
2024-09-23SELLMarket Sell
강명진
Kang Myeong-jin
Managing Director-11.5K₩2,145+51.6%₩25M ($17K)
2024-09-23BUYMarket Buy
강명진
Kang Myeong-jin
Managing Director1.0K₩2,145-51.6%₩2M ($1K)
2024-09-20SELLMarket Sell
강명진
Kang Myeong-jin
Managing Director-41.8K₩2,180+52.4%₩91M ($63K)
2024-09-19SELLMarket Sell
강명진
Kang Myeong-jin
Managing Director-16.0K₩2,130+51.3%₩34M ($24K)
2024-09-13SELLMarket Sell
강명진
Kang Myeong-jin
Managing Director-20.7K₩2,080+50.1%₩43M ($30K)
2024-09-12SELLMarket Sell
강명진
Kang Myeong-jin
Managing Director-5.0K₩2,105+50.7%₩11M ($7K)

Showing the 50 most recent of 51 filings.

Frequently asked questions

Who has been buying Vistos stock?
4 distinct insiders have filed 2 disclosed insider purchases in Vistos (419540), most recently on 2026-06-18. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Vistos have?
Vistos has 2 buy-side and 44 sell-side disclosures on record, covering ₩631M ($438K) in total reported value, spanning 2023-03-29 to 2026-06-18.
Where does StockDrifts get Vistos insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Vistos. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.